
    
      A Multicenter, Randomized, Double-Blind Parallel Group Placebo-Controlled Phase III, Efficacy
      and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an
      Antidepressants in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response
      to Antidepressant Therapy
    
  